Holocene Advisors
PMVP icon

Holocene Advisors’s PMV Pharmaceuticals PMVP Stock Holding History

Holocene Advisors’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-50,000
Closed -$1.77M – 823
2020
Q3 		$1.77M Buy
+50,000
New +$1.84M 0.01% 397

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Holocene Advisors's PMVP Position: Q4 2020 in Review

Holocene Advisors sold out of PMV Pharmaceuticals (PMVP) in Q4 2020, closing a stake of 50,000 shares — an estimated $1.77M sold.

Holocene Advisors first reported a position in PMVP in Q3 2020 and held it in 1 quarter. The position peaked at $1.77M in Q3 2020. 73 funds tracked by Wall St. Rank hold PMVP as of Q4 2020.

  • Holocene Advisors reported no remaining PMV Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Holocene Advisors sold 50,000 PMV Pharmaceuticals shares in Q4 2020, an estimated $1.77M.
  • Holocene Advisors first reported a position in PMV Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Holocene Advisors's PMV Pharmaceuticals position peaked at $1.77M in Q3 2020.
  • 73 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q4 2020.

Based on Holocene Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.